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Abstract
Type 2 diabetes is characterized by cellular and extracellular Mg depletion. Epidemiologic studies showed a high prevalence of hypo-
magnesaemia and lower intracellular Mg concentrations in diabetic subjects. Insulin and glucose are important regulators of Mg metabo-
lism. Intracellular Mg plays a key role in regulating insulin action, insulin-mediated-glucose uptake and vascular tone. Reduced
intracellular Mg concentrations result in a defective tyrosine-kinase activity, post-receptorial impairment in insulin action, and worsening
of insulin resistance in diabetic patients. Mg deWcit has been proposed as a possible underlying common mechanism of the “insulin resis-
tance” of diVerent metabolic conditions. Low dietary Mg intake is also related to the development of type 2 diabetes. BeneWts of Mg sup-
plementation on metabolic proWle in diabetic subjects have been found in most, but not all clinical studies, and larger prospective studies
are needed to support the potential role of dietary Mg supplementation as a possible public health strategy in diabetes risk.
© 2006 Elsevier Inc. All rights reserved. 
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Metabolic syndromeMagnesium (Mg) is the second most abundant intracel-
lular cation after potassium present in living cells. Of the
21–28 g of Mg present in the adult human body, 99% is dis-
tributed in the intracellular compartment, and only 1% in
the extracellular Xuid. Mg is subdivided into three major
compartments of the body: about 65% in the mineral phase
of skeleton, 34% in the intracellular space, and only 1% in
the extracellular Xuid [1]. Small intestine is the main site for
Mg absorption, whereas Mg excretion is mainly performed
through renal pathways. Serum Mg exists in three forms: a
protein-bound fraction (25% bound to albumin and 8%
bound to globulins), a chelated fraction (12%), and the met-
abolically active ionized fraction (Mg-ion: 55%) [2]. The
levels of Mg in the plasma of healthy people are extremely
constant, with a reference interval for total serum levels of
0.75–0.96 mmol/L, and a mean of 0.85 mmol/L. One of the
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doi:10.1016/j.abb.2006.05.007main reasons that Mg metabolism has not become more
the focus of routine attention in clinical practice has been
the diYculties in obtaining an easily available, accurate,
and reproducible measure of Mg status. Total serum
concentrations (MgT) do not reXect the Mg status or
intracellular pool, and intracellular (Mgi) or serum ionized
(Mg-ion) Mg depletion can be seen with normal MgT
concentrations [3,4]. 31P NMR spectroscopic techniques,
although remaining a research based test, are completely
noninvasive and are at present time in 2006 the gold stan-
dard for intracellular measurements of free Mg content in
living tissues in situ [5,6]. For routine clinical use, the devel-
opment of Mg-speciWc ion-selective electrodes (ISE) has
been particularly useful, allowing to measure extracellular
free levels of Mg, with a higher sensitivity than MgT in
detecting subclinical Mg deWcits in several clinical condi-
tions, such as diabetes [3,4].
Although no known hormonal factor is speciWcally
involved in the regulation of Mg metabolism, many hor-
mones are recognized to have an eVect on Mg balance and
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a major role, and catecholamines also inXuence Mg metab-
olism [7]. A role for insulin has been proposed, and accu-
mulating data have conWrmed that insulin is a key hormone
in the regulation of the Mg metabolism [1,8].
Insulin as a regulatory hormone of magnesium metabolism
Insulin has speciWc ionic eVects to stimulate the trans-
port of Mg from the extracellular to the intracellular com-
partment, thus increasing Mgi content [9]. Using gold
standard NMR techniques to measure Mgi in vitro in
erythrocyte from nondiabetic healthy individuals, we have
showed an ionic action of insulin that is speciWc, dose-
related, and independent of cellular glucose uptake [9–11].
The mechanism by which insulin acutely increases Mgi con-
tent is still in question. Insulin might induce alterations in
ion Xuxes, particularly by stimulating the Na+/H+ antipor-
ter either directly or via diacylglycerol-protein-kinase C
[10], or by inhibiting Ca-ATPase activity [11]. Furthermore,
there are indications that, as in other energy-producing sys-
tems, an ATPase dependent pump is involved in the mecha-
nism by which insulin regulates erythrocyte Mg content.
The insulin-mediated Mgi accumulation may depend upon
the activation of the tyrosine-kinase insulin receptor since
the insulin eVect on intracellular Mg is totally abolished by
a monoclonal antibody directed towards the insulin recep-
tor [12]. Furthermore, there are indications that, as in other
energy producing systems, an ATPase-dependent pump is
involved in the mechanism by which insulin regulates the
erythrocyte Mg content.
Magnesium as a modulator of insulin action and insulin 
sensitivity
The relationship between insulin and Mg is a complex
one. Insulin regulates Mg homeostasis but, in turn, Mg
itself is a major determinant of insulin and glucose metabo-
lism. An increasing number of evidences have suggested a
clinical relevance for the altered Mg metabolism present in
states of increased peripheral insulin resistance. Mg is a
necessary cofactor in over 300 enzymatic reactions and spe-
ciWcally in all phosphorylation processes, and in general in
all reactions that involve the utilization and transfer of
ATP, including cellular responses to growth factors and cell
proliferation [13,14]. Mg-ion, although not directly
involved in the biochemical process of contraction, modu-
lates vascular smooth muscle tone and contractility by
aVecting calcium ion concentrations and its availability at
critical sites. Mg-ions directly inXuence baseline tension,
vascular tone, and vascular responsiveness to pressor
agents [15]. Diabetes or insulin resistance causes a signiW-
cant impairment in the relaxation responses to Mg and
aggravates the alteration in Mg-induced vascular relaxa-
tion observed in pregnancy [16].
Intracellular Mg is a critical cofactor for several enzymes
in carbohydrate metabolism, and because of its role as partof the activated Mg-ATP complex required for all of the
rate-limiting enzymes of glycolysis, regulates the activity of
all enzymes involved in phosphorylation reactions. Mg con-
centration is critical in the phosphorylation of the tyrosine-
kinase of the insulin receptor as well as all other protein-
kinases, all ATP and phosphate transfer-associated
enzymes, such as the Ca-ATPases in plasma membrane and
endoplasmic reticulum. Mg deWciency may result in disor-
ders of tyrosine-kinase activity on the insulin receptor,
event related to the development of post-receptorial insulin
resistance and decreased cellular glucose utilization [17]
that is, the lower the basal Mg, the greater the amount of
insulin required to metabolize the same glucose load, indi-
cating decreased insulin sensitivity. SpeciWcally, in skeletal
[18] and in heart [19] muscle and fat tissue [20], insulin resis-
tance would be the expected outcome in the presence of
suppressed cellular Mg. As such, in mouse skeletal muscle
increased Mg eZux from cells was associated with inhibi-
tion of insulin-stimulated glucose uptake. SigniWcant decre-
ments in the insulin signaling enzyme activities can already
be observed at the range of Mg values seen in disease states
such as type 2 diabetes mellitus and hypertension [21].
Determination of intracellular free Mg concentrations
using 31P NMR has revealed that cellular concentrations of
Mgi are in the 100–300 nM range, which is close to the dis-
sociation constant of many enzymes systems using ATP or
phosphate transfer. Since tissue Mg uptake is regulated by
insulin, then impairment of this process by insulin resis-
tance could either cause or exacerbate intracellular Mg deW-
ciency.
Glucose as physiologic determinant of cellular magnesium
Glucose appears to contribute to cellular ion homeosta-
sis independently of insulin. The role of hyperglycemia in
the intracellular Mg depletion of diabetes has been con-
Wrmed by research from our group indicating that hyper-
glycaemia both in vivo after oral glucose loading [22] and
in vitro, independently of insulin or other in vivo responses
to oral glucose ingestion [23,24], directly induces suppres-
sion of Mgi. SpeciWcally, the transient hyperglycemia of
oral glucose loading reproduces in normal subjects the
same altered ionic proWle of depleted Mgi/increased Cai
levels that occurs chronically in diabetic subjects [25], which
dynamically appears to be equally and inversely true for
serum ionized Mg [22]. This glucose-mediated ionic eVects
are independent of insulin action, since hyperglycemia
induces ionic changes both in VSMC [26], and in red cells
[23,24], where glucose transport is unaVected by insulin,
and are clinically signiWcant since they occur at glucose
concentrations achieved clinically (10 mM), in vivo in sub-
jects with impaired glucose tolerance as well as frank diabe-
tes mellitus. Since hyperglycemia per se signiWcantly
contributes to insulin resistance in diabetes mellitus [27]
and because reducing Mgi promotes vasoconstriction [28],
it is possible to hypothesize a role of this glucose-induced
Mg changes in the vasoconstriction present in chronic
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fasting blood glucose and HbA1c levels (reXective of aver-
age glycemic levels over time in diabetic subjects) to cellular
ion levels support the clinical signiWcance of these in vitro
glucose induced changes [1,30,31], suggesting that circulat-
ing glucose concentrations, even within the “normal”
range, may be a physiologic determinant of cytosolic Mg
concentrations.
Cellular magnesium as a determinant of “Ionic Insulin 
Resistance” and cellular responsiveness
The overall hypothesis that Mgi content is a crucial
determinant of cellular responsiveness is supported by data
showing that the ability of insulin and glucose at physiolog-
ically maximal concentrations to stimulate Mgi is impaired
in cells, in which the basal Mg content is reduced. The
in vitro glucose-independent ionic eVects of insulin are
blunted in cells with a reduced basal Mgi content [32]. Con-
tinuous relationships were observed between basal Mgi val-
ues and Mgi responses to insulin, i.e., the lower the basal
Mgi, the less responsive is the cell to insulin stimulation,
conWrming that insulin action is strictly dependent from the
cellular Mgi concentration. Similarly, altered cellular
behavior was found in cells responsiveness to glucose
action. Glucose-induced changes in Mgi levels were closely
related to basal Mgi levels. For all subjects cellular Mg
responsiveness to insulin or glucose was closely and directly
related to basal Mgi levels—the lower the basal Mgi, the
less the Mgi rose in response to insulin (or glucose) [32].
These results conWrm that although Mgi levels may be reg-
ulated by ambient glucose and insulin levels, in turn, basal
Mgi environment inXuences the cellular ionic responses to
insulin and glucose. These data also provide at least one
mechanism—the lowering of intracellular free Mgi, by
which hyperglycemia itself contributes to insulin resistance.
One question arising from these observations was
whether this cellular ionic resistance to insulin reXected a
unique abnormality of cellular insulin action or whether it
represented a more general property of cells, in which cellu-
lar Mg deWciency necessarily also alters cellular ionic
responses to other nonhormonal stimuli as well. Thus, fol-
lowing an oral glucose tolerance test, the rate of glucose
disappearance from the circulation was inversely related to
the basal skeletal muscle free Mg content in the same man-
ner—the lower the Mgi, the slower the decrease in extracel-
lular glucose and the more blunted the Mg uptake
(unpublished data). This is consistent with an a priori cellu-
lar Mg deWciency as the cause of, rather than merely the
result of, peripheral insulin resistance [22]. The primacy of
Mgi levels in determining insulin action, rather than vice
versa, was also suggested by the induction of cellular insu-
lin resistance in normal cells following intracellular Mg
depletion to levels observed in hypertensive or diabetic cells
[32]. Hence, regardless of the primary origins of glucose
intolerance and insulin resistance in syndromes such as
hypertension or diabetes, it is emphasized the potential con-tribution of altered cellular Mgi as an independent determi-
nant of glucose and insulin action. Decreasing Mgi in cells
from normal individuals rendered them resistant to the
ionic eVects of insulin, an eVect indistinguishable from the
insulin resistance observed in cells from hypertensive sub-
jects [32]. Altogether, these data demonstrating ionic
aspects of cellular insulin resistance has led us to hypothe-
size that the “insulin resistance”, currently deWned by mea-
surements of tissue glucose uptake, might equally well be
deWned on the basis of altered cellular ion responsiveness.
These data support the overall hypothesis that the intracel-
lular ionic milieu is at least one determinant of physiologi-
cal cellular responsiveness to extracellular stimuli. Thus, the
“ionic” insulin resistance is probably not speciWc for insu-
lin, but may rather be one tissue manifestation of a general
property of cells in which steady-state Mgi may determine
cell responsiveness to insulin, glucose or to other external
stimuli. The relevance of altered cellular Mg metabolism to
tissutal insulin sensitivity suggest a critical role of Mg in
contributing to the clinical coincidence of Mg depletion to
states of insulin resistance such as hypertension, metabolic
syndrome, type 2 diabetes as well with the increased inci-
dence of each of these conditions with age, a condition itself
characterized by a tendency to Mg depletion. Thus, Mgi
depletion can directly promote tissutal insulin resistance
and altered vascular tone, thus helping to understand the
mechanisms underlying the clinical association among
these apparently disparate conditions (Fig. 1).
Magnesium deWciency in type 2 diabetes mellitus
Diabetes is frequently associated with both extracellular
and intracellular Mg depletion. Epidemiologic studies have
found an high prevalence of hypomagnesaemia in subjects
with type 2 diabetes, especially in those with poorly con-
trolled glycemic control [3,33–36]. In diabetic subjects,
plasma Mg levels are inversely correlated to the metabolic
control [33]. Because of the lack of sensitivity of MgT, a
depletion in intracellular and serum ionized Mg can be
Fig. 1. Overall hypothesis in which intracellular Mg deWciency may medi-
ate the relationship between insulin resistance, hypertension, metabolic
syndrome, and type 2 diabetes mellitus.
M. Barbagallo, L.J. Dominguez / Archives of Biochemistry and Biophysics 458 (2007) 40–47 43found in many subjects with total serum Mg still in the
normal range. Using the Nova-8 Mg ion-selective electrode
(ISE) to measure serum ionized Mg in a preliminary sample
of 50 subjects with type 2 diabetes, we have recently found
signiWcantly lower Mg-ion levels compared to normal con-
trols (0.49 + 0.01 mmol/L vs. 0.52 + 0.01 mmol/L, p < 0.05),
without signiWcant changes in MgT (Fig. 2). Resnick et al.
measured concurrently MgT, Mg-ion and Mgi levels in the
same subjects using 31P NMR and the ISE Mg-selective
electrode, and found that only both Mgi and Mg-ion (but
not serum total MgT) were signiWcantly reduced diabetic
subjects, and that a close direct relationship was present
between the ionized extra and the intracellular Mg mea-
surement [3].
Among the mechanisms that may favor Mg depletion in
diabetes the most important are a low Mg intake and an
increased Mg urinary loss, while dietary Mg absorption
and retention are not impaired in patients with type 2 dia-
betes [37]. With regard to low Mg intake, changes in dietary
habits in the western world have resulted in daily Mg intake
close to, or even below, the recommended daily allowances.
The ARIC study found a signiWcant inverse correlation
between dietary Mg and the incidence of type 2 diabe-
tes[38]. Diabetes is associated with renal calcium and Mg
wasting [39,40], but the molecular mechanisms of these
defects are unknown [41]. Plasma Mg levels were found
inversely correlated with the urinary Mg excretion rate and
with fasting blood glucose values, suggesting that the tubu-
lar reabsorption of Mg is decreased in presence of severe
hyperglycemia [39]. An increased renal Mg transporter
abundance was found in STZ-induced diabetic rats that
may represent a compensatory adaptation for the increased
load of Mg to the distal tubule. Insulin administration com-
pletely corrected the hyperglycemia-associated hypercalciu-
ria and hypermagnesiuria, and reversed the increase of Mg
transporter abundance [41]. An improved metabolic con-
trol was associated with reduced urinary Mg losses [35].
Hyperinsulinemia per se may also contribute to the urinary
Mg depletion [40] and the reduced sensitivity to insulin may
itself aVect Mg transport. As additional factors, hyperglyce-
mia in the absence of a good metabolic control may have a
Fig. 2. Ionized Mg levels (Mg-ion, mmol/L) in type 2 diabetic subjects vs.
normal controls.role in the increased urinary Mg excretion, and the use of
loop and thiazide diuretics also promote Mg wasting.
At the cellular level, cytosolic free Mgi levels are consis-
tently reduced in subjects with type 2 diabetes mellitus
[25,30,42–44]. Using gold standard NMR techniques, our
group have shown signiWcantly lower steady-state Mgi and
reciprocally increased Cai levels in subjects with type 2 dia-
betes, compared with young nondiabetic subjects [25,30]
(Fig. 3).
An alteration of the basal and cation-stimulated Mg2+
Xuxes and transport across the plasma membrane [45] and
of the Na+/Mg2+ exchanger [46], which could extrude but
not accumulate Mg in exchange for Na has been found in
diabetic liver cells [47]. The impairment of Mg uptake
mechanism, in addition to the decrease in cellular ATP
level, may contribute, at least in part, to explaining the
decrease in cellular Mg content observed under diabetic
conditions.
Mgi depletion in diabetes has been shown to be clinically
and pathophysiologically signiWcant, since Mgi levels quanti-
tatively and inversely predict the fasting and post glucose lev-
els of hyperinsulinemia, as well as peripheral insulin
Fig. 3. Upper panel: relationship between age and cytosolic free magne-
sium (Mgi) levels in healthy normotensive nondiabetic subjects. Lower
panel shows the eVect of age on Mgi levels in healthy normals, in hyper-
tensive (HTN) and in type 2 diabetic (DM2) subjects. Full bars indicate
data from young-middle age subjects(<65 yo) and empty bars indicate
data from old age subjects (>65 yo) (Ref. [32]).
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[6,48]. SpeciWcally, (a) fasting insulin levels [25,49]; (b) the
integrated insulinemic response to a standard oral glucose
tolerance test [49]; (c) the steady-state plasma glucose
response to insulin infusion and indices for peripheral insulin
sensitivity derived from euglycemic hyperinsulinemic clamps
[50,51], are all inversely related to Mg levels, whether mea-
sured as Mgi in situ in brain, free or total Mg in peripheral
red cells [8,49,51,22]or even as circulating Mg [52]. Further-
more, direct and inverse relations, respectively, are observed
between steady-state fasting levels of Mgi and fasting blood
glucose, blood pressure, HbA1c, and the glycemic and insuli-
nemic response to oral glucose loading in normal, hyperten-
sive, and diabetic subjects—the lower the Mgi, the higher the
blood pressure and the more hyperinsulinemic the response
to oral glucose loading [25,30,49,31,53].
Aging is frequently associated with insulin resistance
and glucose intolerance. We have speciWcally studied the
behavior of ion content with age and have showed a contin-
uous age-dependent fall of Mgi levels in peripheral blood
cells of healthy elderly subjects, these alterations being
indistinguishable from those occurring, independently of
age, in essential hypertension or type 2 diabetes [30]. In
other terms, essential hypertension and/or type 2 diabetes
appear to determine an acceleration of natural age-depen-
dent Mg depletion suggesting that these ionic changes may
be clinically signiWcant, underlying the predisposition in
elderly subjects to cardiovascular and metabolic diseases,
and might therefore help to explain the age-related
increased incidence of these diseases [30,54] (Fig. 3). Lower
Mg levels may not only be a consequence, but may also pre-
dispose to diabetes. In a national population-based cross-
sectional nutrition survey in Taiwan, hypomagnesemia was
associated with an increased risk of diabetes. Thus, the risk
of diabetes was elevated 3.25 times at plasma Mg levels
lower than <0.863 mmol/L [55].
The link between Mg deWciency and the development of
insulin resistance and type 2 diabetes is strengthened by the
observation that several treatments for diabetes appear to
increase Mg levels. Metformin, for example, raises Mg lev-
els in the liver [56]. Pioglitazone, a thiazolidinedione antidi-
abetic agent that increases insulin sensitivity have positive
actions on Mg metabolism both in vitro, and in vivo stimu-
lating free Mg concentration in adipocytes [20] and increas-
ing serum Mg in subjects who received pioglitazone [57].
Other insulin mimeting substances such as vanadate and
IGF-1 are also associated to a direct eVect to stimulate Mgi
levels [58], and the eVects of antioxidants glutathione and
vitamin E to improve glucose and insulin metabolism may
derive, at least in part, from their action on Mg metabolism
[50,51]. The eVects of glutathione on peripheral insulin sen-
sitivity are associated to a speciWc action of glutathione to
increase intracellular Mg, and with a direct relation of
euglycemic clamp-derived glucose disposal (WBGD) indi-
ces in vivo with intracellular Mg levels [50] (Fig. 4).
Altogether, independent to the cause of poor plasma and
intracellular Mg content, a depletion of Mg seems to be acofactor for a further derangement of insulin resistance
[1,59]. Mg deWciency, which may take the form of a chronic
latent Mg deWcit rather than clinical hypomagnesemia, may
have clinical importance because of the crucial role of Mg
as a cofactor in many enzymatic reactions regulating glu-
cose metabolism. A deWcient Mg status may not just be a
secondary consequence of type 2 diabetes but may precedes
and cause itself insulin resistance and altered glucose toler-
ance, and even type 2 diabetes [1,8,29]. We have suggested a
role for Mg deWcit as a possible unifying mechanism of the
of conditions associated to “insulin resistance”, including
type 2 diabetes mellitus, metabolic syndrome, essential
hypertension [1,53,54] (Fig. 1).
Magnesium deWciency and vascular diabetic complications
Mg deWciency has been proposed as a factor implicated
in the pathogenesis of diabetes complications. Cellular
ionic alterations are related to the cardiovascular structural
alterations often present in diabetes. A signiWcant relation
was found between fasting levels of Mgi levels and cardio-
vascular structural indices [31]. In diabetic subjects, even in
the absence of elevated blood pressure, suppressed Mgi lev-
els are associated with cardiac hypertrophy, and speciWcally
with increased echocardiographically measured posterior
wall thickness and left ventricular mass index in both dia-
betic and/or hypertensive subjects [31]. When combined,
hypertension and diabetes were associated with further
deviated ion levels and a greater extent of cardiac hypertro-
phy. Similarly, magnetic resonance imaging (MRI)—deter-
mined values for aortic distensibility in normal and
hypertensive humans were closely and positively related to
concomitantly measured levels of Mgi measured in situ in
brain and skeletal muscle tissue by 31P NMR magnetic res-
onance spectroscopic (MRS) techniques: the more sup-
pressed the Mgi, the stiVer (less distensible) the aorta [60].
In children and adolescent patients with type 1 diabetes,
serum Mg levels have been associated with early atheroscle-
rosis, and a signiWcant relationships was found between
Fig. 4. Relations of whole body glucose disposal (WBGD) to intracellular
Mg. The relation to WBGD was also true when hypertensive (empty cir-
cles), and normotensive (full circles) subgroups were analyzed individually
(normotensives: r D 0.50, P < 0.01; hypertensives: r D 0.56, P < 0.01). FFM
indicates fat-free mass (Ref. [49]).
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functions of common carotid artery, accepted as markers of
early carotid atherosclerosis [61]. In patients with type 2
diabetes mellitus, low circulating Mg levels have been asso-
ciated also with a more rapid decline of renal function [62].
To conWrm the potential role of Mg deWcits in the patho-
genesis of diabetic vascular complications, in an experimen-
tal model of diabetes in rats, Soltani has recently suggested
a potential role for oral Mg supplementation in the preven-
tion of the vascular complications of the disease [63,64],
and of the pathological changes in the aorta and pancreas
of diabetic rats [65]. Mg may also be related to altered ther-
mal pain threshold in diabetes. Thus, oral Mg administra-
tion given at the time of diabetes induction was able to
restore thermal hyperalgesia, Mg deWciency and hypergly-
cemia in diabetic rats [66].
Magnesium metabolism and the metabolic syndrome
The presence of a metabolic syndrome is also associated
with altered Mg metabolism [67–69]. Corica et al. recently
showed that type 2 diabetics having a high risk lipid proWle,
high blood pressure or abdominal adiposity had lower cir-
culating ionized Mg levels with respect to patients without
metabolic risk factors. Furthermore, plasma triglycerides
and waist circumference are independently associated with
hypomagnesemia [68]. Guerrero-Romero found an interac-
tion among Mg levels, risk for metabolic syndrome and
inXammation and oxidative stress [69]. Decreased serum
Mg levels have been found in the insulin resistance associ-
ated to nonalcoholic steatohepatitis (NASH) in obese sub-
jects [70].
Since, hypomagnesemia may contribute to the patho-
physiology of cardiovascular diabetes complications by
altering blood lipid proWle in a way that predispose to ath-
erosclerosis, the association of Mg depletion with metabolic
syndrome may oVer another mechanism by which an alter-
ation of Mg homeostasis may favour the onset and progres-
sion of diabetic complications. In agreement with this, oral
Mg supplementation in patients with type 2 diabetes
resulted in a signiWcant decrease in total and LDL choles-
terol, and an increase in HDL cholesterol [71]. Huerta et al.
recently reported serum and dietary Mg deWciency in obese,
insulin resistant nondiabetic children. Both serum and die-
tary Mg were inversely correlated with fasting insulin [72].
In postmenopausal non diabetic women intracellular Mg
was found to be directly related with insulin sensitivity, body
composition and free fat mass [73], conWrming that both Mg
deWcit and obesity may independently lead to a higher risk
for insulin resistance and cardiovascular disease [73].
He et al. have prospectively examined the relations
between Mg intake and incident metabolic syndrome and
its components among 4637 Americans, aged 18–30 years,
who were free from metabolic syndrome and diabetes at
baseline. During the 15 years of follow-up, 608 incident
cases of the metabolic syndrome were identiWed. Mg intake
was inversely associated with incidence of metabolic syn-drome after adjustment for major lifestyle and dietary vari-
ables and baseline status of each component of the
metabolic syndrome. Mg intake was also inversely related
to individual component of the metabolic syndrome and
fasting insulin levels, suggesting that higher Mg intake may
protect against the risk of development of metabolic syn-
drome [74].
Role of dietary magnesium deWciency on insulin resistance 
and possible therapeutical eVects of Mg supplements in DM2
The hypothesis that alterations of Mg metabolism
would induce and/or exacerbate insulin resistance is con-
Wrmed by data, in both humans and experimental animals,
showing that dietary-induced Mg deWciency is correlated
with insulin resistance [74–80]. A Mg-deWcient diet in sheep
has been found to be associated with a signiWcant impair-
ment of insulin-mediated glucose uptake [75] while Mg sup-
plementation delayed the development of diabetes in a rat
model of diabetes [76]. Higher Mg intake is associated with
lower fasting insulin concentrations among women without
diabetes [77], and a signiWcant negative correlation is pres-
ent between total dietary Mg intake and the insulin
responses to an oral glucose tolerance test [78]. Rats fed a
low Mg diet showed a signiWcant increase in blood glucose
and triglyceride levels [79]. Suarez et al. investigated the
eVect of dietary-induced Mg deWciency on glucose disposal,
glucose-stimulated insulin secretion and insulin action on
skeletal muscle in rats, which were fed a low Mg-containing
diet. Mg depletion provoked a deleterious eVect on glucose
metabolism due to an impairment of both insulin secretion
and action. In rats, maternal Mg restriction induces insulin
resistance in pups by six months of age, whereas additional
perinatal Mg deWciency impairs glucose tolerance [80]. The
insulin resistance observed in skeletal muscle of Mg-deW-
cient rats was linked, at least in part, to a defective tyrosine-
kinase activity of insulin receptors [81]. Mg intake is related
not only to insulin sensitivity but also to the development
of diabetes. DeWciencies of both dietary Mg and serum
plasma Mg content have been associated with an increased
risk to develop glucose intolerance and diabetes
[33,38,82,83] an increased Mg intake is associated with a
signiWcant decline in the incidence of type 2 diabetes [84].
Recent epidemiological data have shown a signiWcant
inverse association between Mg intake and diabetes risk
supporting the priority of Mg deWcit in the development of
insulin resistance, metabolic syndrome and diabetes
[74,85,86]. 85,060 women and 42,872 men, who had no his-
tory of diabetes or cardiovascular disease at baseline, had
been followed, respectively, for 18 (women) and 12 (men)
years, and the risk for type 2 diabetes in the upper quintile
of Mg intake, as compared to that in the bottom quintile,
was about a third lower after adjustment for a number of
potentially confounding variables; and there was a signiW-
cant inverse association between Mg intake and diabetes
risk [85]. In the Women’s Health Study, a cohort of 39,345
United States women aged 745 years with no previous
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were followed for an average of six years. 918 conWrmed
incident cases of type 2 diabetes were documented, and a
signiWcant inverse association was found between Mg
intake and risk of type 2 diabetes, independent of age and
BMI, supporting a protective role of higher intake of Mg in
reducing the risk of developing type 2 diabetes [86].
Thus, taking into account that hypomagnesaemia has
been associated with an increased risk to develop glucose
intolerance and diabetes [38], the use of Mg supplements
could be an alternative tool for the prevention of type 2 dia-
betes and metabolic syndrome, a hypothesis that needs to
be conWrmed by speciWc and well designed trials with Mg
[87,88]. However, the eVects of Mg supplements on the met-
abolic proWle of diabetic subjects are controversia [89], ben-
eWts having been found in some [90–92], but not all clinical
studies [93]. DiVerences in baseline Mg status and meta-
bolic control may explain the diVerences among these stud-
ies. Mg may mediate the favorable impact of whole grains
on insulin sensitivity cereal on insulin sensitivity [94–97].
A recent clinical trial speciWcally conducted among type
2 diabetes with low MgT levels (index of an already
advanced Mg deWcit) found a beneWcial eVect of oral Mg
supplementation on fasting and postprandial glucose levels
and insulin sensitivity [89], and we have shown an improve-
ment in insulin-mediated glucose uptake measured by
euglycemic insulin clamp and a signiWcant relationship
between the parallel increase in plasma and erythrocyte Mg
concentration and the progressive increase in the insulin
sensitivity in diabetic patients that were supplemented with
increased dosage of Mg supplements [8]. Among non-dia-
betic, apparently healthy subjects there are also some evi-
dences of a relatively small but signiWcant beneWcial eVects
of Mg supplements on insulin sensitivity [90]. The fact that
most but not all diabetic subjects have a Mg deWciency and
that no large clinical trial have been speciWcally focused on
subjects with a Mg deWcit, diagnosed with an accurate and
reliable technique, may help to explain the discrepancy
between the unclear role of supplemental Mg on glycemic
control in diabetics, and the signiWcant impact on diabetes
risk in prospective epidemiologic studies [85]. Longer-term
therapeutic trials of Mg in diabetes mellitus are clearly
needed in the near future to narrow this gap.
Conclusions
Altogether, these accumulating evidence conWrm (a) the
critical importance of Mg metabolism in regulating insulin
action and sensitivity (pathophysiologically, Mg depletion
can directly cause tissutal insulin resistance); (b) that Mg
deWciency, deWned on the basis of intracellular free Mg lev-
els, and or serum ionized Mg (Mg-ion) is a common feature
of type 2 diabetes mellitus, metabolic syndrome and other
insulin resistant states; (c) the possible role of cellular Mg
as a underlying common mechanism of the “insulin resis-
tance” of metabolic diseases including the metabolic syn-
drome, essential hypertension, altered glucose tolerance,and type 2 diabetes; (d) that low dietary Mg intake is
related not only to insulin sensitivity but also to the devel-
opment of type 2 diabetes mellitus, and that further pro-
spective studies are needed to support the potential role of
dietary Mg supplementation as a possible public health
strategy to reduce diabetes risk in the population.
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